Senores Pharmaceuticals Limited has announced significant changes in its senior management personnel, with the appointment of a new Chief Technology Officer and the resignation of its President – Research and Development, both effective March 17, 2026.

Board Approves New CTO Appointment

The company's Board of Directors, through a circular resolution passed on March 17, 2026, approved the appointment and categorization of Mr. Jatin Gajjar as Chief Technology Officer and Senior Management Personnel. This decision was made based on the recommendation of the Nomination and Remuneration Committee, in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Senior Management Personnel Changes

New CTO's Professional Background

Mr. Jatin Gajjar brings over three decades of leadership experience in pharmaceutical technology, manufacturing operations, and product development to his new role. His expertise encompasses:

• Complex formulations and regulatory compliance
• Process optimization and novel drug delivery technologies
• Strategic leadership across R&D, manufacturing, and regulatory affairs
• Regulatory approvals and commercialization across key markets

Prior to joining Senores Pharmaceuticals, Mr. Gajjar served as President at QuoSolve Pharmaceutical Consultants and held leadership roles at several global pharmaceutical organizations including Amneal Pharmaceuticals, Sun Pharmaceutical Industries, Alembic, Zydus Cadila, Torrent Pharma, and Aventis Pharma.

Educational Qualifications

Mr. Gajjar holds comprehensive academic credentials in the pharmaceutical field:

• Bachelor's degree in Pharmacy from L.M. College of Pharmacy, Gujarat University
• Master's degree in Pharmacy from L.M. College of Pharmacy, Gujarat University
• Diploma in Marketing and Sales Management from RPICM, Bharatiya Vidya Bhavan

R&D Head Departure

Concurrently, Mr. Manohar Lalge, who served as President – Research and Development, tendered his resignation effective from the close of business hours on March 17, 2026. Upon his resignation, he ceased to be Senior Management Personnel of the company. The resignation letter, dated January 19, 2026, was formally accepted by the company's HR department.

Regulatory Compliance

The company has fulfilled all regulatory requirements by filing the necessary disclosures with both BSE Limited and the National Stock Exchange of India Limited. The information has also been uploaded on the company's website at www.senorespharma.com , ensuring complete transparency with stakeholders and regulatory authorities.

Renosen Pharmaceuticals Private Limited has submitted a revised disclosure to BSE Limited regarding the release of pledge on 4,00,000 equity shares of Senores Pharmaceuticals Limited under Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Regulatory Compliance Update

The revised disclosure, dated March 12, 2026, was submitted following BSE's email dated March 10, 2026, which observed that the earlier disclosure dated February 16, 2026, did not specify the "reason for encumbrance." The exchange had requested clarification on the reason for creation, release, or invocation of pledged shares.

Pledge Release Details

The disclosure pertains to the release of pledge on 4,00,000 equity shares of Senores Pharmaceuticals Limited. The key details of the transaction are presented below:

Current Shareholding Position

Renosen Pharmaceuticals Private Limited, formerly known as Senores Lifesciences Pvt. Ltd., currently holds 27,08,719 equity shares in Senores Pharmaceuticals Limited, representing 5.8817% of the total share capital. The company is classified as a promoter group entity in the shareholding structure.

Promoter Group Holdings

The disclosure also provides a comprehensive overview of the promoter and promoter group holdings in Senores Pharmaceuticals Limited:

Corporate Information

The disclosure was signed by Swapnil Jatinbhai Shah, Director of Renosen Pharmaceuticals Private Limited (DIN: 05259821), and submitted to BSE Limited under scrip code 544319. Senores Pharmaceuticals Limited is listed on both BSE Limited and National Stock Exchange of India Limited.

The revised disclosure ensures compliance with SAST regulations and provides transparency regarding the encumbrance activities of promoter group entities.